A Randomized, double-blind, placebo-controlled Phase 3

Project: Research project

Project Details

Description

A Randomized, double-blind, placebo-controlled Phase 3 study of SGN-35 and Best supportive care vs. Placebo and BSC i the treatment of patients at high risk of residual Hodgkin Lymphoma (HL) following autologous stem cell transplant (ASCT)
StatusActive
Effective start/end date8/5/1012/31/20

Funding

  • Seattle Genetics, Inc.

Fingerprint Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.